The estimated Net Worth of Brian L Durkin is at least $8.06 Million dollars as of 9 March 2022. Mr. Durkin owns over 18,628 units of Abbvie Inc stock worth over $3,715,501 and over the last 6 years he sold ABBV stock worth over $4,347,372. In addition, he makes $0 as Vice President and Controller at Abbvie Inc.
Brian has made over 4 trades of the Abbvie Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 18,628 units of ABBV stock worth $2,794,386 on 9 March 2022.
The largest trade he's ever made was selling 18,628 units of Abbvie Inc stock on 9 March 2022 worth over $2,794,386. On average, Brian trades about 2,165 units every 68 days since 2019. As of 9 March 2022 he still owns at least 19,094 units of Abbvie Inc stock.
You can see the complete history of Mr. Durkin stock trades at the bottom of the page.
Brian L. Durkin serves as Vice President, Controller of the Company. Mr. Durkin previously served as Vice President, Internal Audit from 2016 to 2018. Prior to joining AbbVie, he served as Vice President of Finance and Division Controller for Abbott’s Vision Care business from 2009 to 2016 and Controller Pharmaceutical Research and Development from 2005 to 2009. Mr. Durkin joined Abbott in 1986.
Brian Durkin is 58, he's been the Vice President and Controller of Abbvie Inc since 2018. There are 13 older and 17 younger executives at Abbvie Inc. The oldest executive at Abbvie Inc is Edward Liddy, 73, who is the Independent Director.
Brian's mailing address filed with the SEC is North Waukegan Road, North Chicago, Lake County, Illinois, 60044, United States.
Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell, and Glenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
Abbvie Inc executives and other stock owners filed with the SEC include: